Abstract
EGFR Inhibitors are used to treat Non-Small-Cell Lung Cancer (NSCLC) and colorectal cancer (CRC). A common side effect of EGFR Inhibitors is a follicular/pustular skin eruption. We report a case of gefitinib (Iressa) associated skin eruption. The treatment regimen consisted of triamcinolone 0.1% cream twice daily, clindamycin 1% lotion twice daily and sodium sulfacetamide lotion twice daily. The clinical presentation, etiology, and management options of EGFR Inhibitor associated skin eruptions are discussed.
MeSH terms
-
Aged
-
Anti-Bacterial Agents / therapeutic use
-
Anti-Infective Agents, Local / therapeutic use
-
Anti-Inflammatory Agents / therapeutic use
-
Antineoplastic Agents / administration & dosage
-
Antineoplastic Agents / adverse effects
-
Antineoplastic Agents / therapeutic use
-
Carcinoma, Non-Small-Cell Lung / drug therapy
-
Clindamycin / therapeutic use
-
Drug Eruptions / drug therapy
-
Drug Eruptions / etiology*
-
Drug Therapy, Combination
-
ErbB Receptors / antagonists & inhibitors*
-
Gefitinib
-
Humans
-
Lung Neoplasms / drug therapy
-
Male
-
Quinazolines / administration & dosage
-
Quinazolines / adverse effects*
-
Quinazolines / therapeutic use
-
Sulfacetamide / therapeutic use
-
Triamcinolone / therapeutic use
Substances
-
Anti-Bacterial Agents
-
Anti-Infective Agents, Local
-
Anti-Inflammatory Agents
-
Antineoplastic Agents
-
Quinazolines
-
Triamcinolone
-
Clindamycin
-
Sulfacetamide
-
ErbB Receptors
-
Gefitinib